Even among women with breast implants, just over half have heard of BIA-ALCL.
AALL0434, one of the largest prospective studies of T-LL, resulted in successful disease-free and overall survival outcomes.
Flow cytometry may provide an efficient, sensitive, and specific tool for the differential diagnosis of breast implant–associated ALCL, but a cell block may be able to answer additional questions about the disease.
For pediatric high-risk B-cell NHL, adding rituximab to standard LMB chemotherapy prolongs event-free and overall survival but may increase adverse events.
In this patient case, significant neurological adverse effects associated with nelarabine were noted at 30 days following initiation of therapy.